Table 1. BMT pairs, disease, and transplant characteristics.
| Acute GVHD | ||
| CHARACTERISTICS | Gr 0-I | Gr II-IV |
| RECIPIENTS | n = 59 | n = 48 |
| Male/Female | 40/19 | 27/21 |
| Median age, y (range) | 36 (6–66) | 40 (7–66) |
| Positive CMV Serology | 35 (59%) | 27 (56%) |
| Underlying diagnosis | ||
| - Chronic Leukemia | 3 (5.1%) | 6 (12.5%) |
| - Acute Leukemia | 25 (42.4%) | 25 (52.1%) |
| - Other malignant hemopathies | 11 (18.6%) | 6 (12.5%) |
| - Myelodysplasia | 5 (8.5%) | 7 (14.6%) |
| - Aplasia | 15 (25.4%) | 4 (8.3%) |
| DONORS | ||
| Male/Female | 30/29 | 25/23 |
| Median age, y (range) | 33 (5–65) | 36 (21–66) |
| Female donor to male recipient | 17 (29%) | 13 (27%) |
| Positive CMV Serology | 31 (53%) | 30 (62.5%) |
| TRANSPLANTATION | ||
| Donor | ||
| - SIB | 49 (83%) | 37 (77%) |
| - MUD | 10 (17%) | 11 (23%) |
| Source of cells | ||
| - PB | 35 (59%) | 27 (56%) |
| - BM | 24 (41%) | 21 (44%) |
| Conditioning | ||
| - Nonmyeloablative | 25 (42%) | 16 (33%) |
| - TBI-based | 17 (29%) | 23 (48%) |
| - Busulfan-based | 24 (41%) | 19 (40%) |
| GVHD Prophylaxis | ||
| - CSA | 1 (2%) | 0 (0%) |
| - CSA+MTX | 29 (49%) | 28 (58%) |
| - CSA+MMF | 15 (25%) | 14 (29%) |
| - CSA+Others | 2 (3%) | 1 (2%) |
| - Tacrolimus | 1 (2%) | 1 (2%) |
| Acute GVHD grades: | ||
| - 0 | 46 (78%) | |
| - 1 | 13 (22%) | |
| - 2 | 35 (73%) | |
| - 3 | 11 (23%) | |
| - 4 | 2 (4%) | |
No significant difference was found between these two groups for the characteristics listed. BMT: bone marrow transplantation; SIB: HLA-matched sibling, MUD: HLA-matched unrelated donor; PB: peripheral blood; BM: bone marrow; TBI: Total body irradiation; CSA: cyclosporin A; MTX: Methotrexate; MMF: Mycophenolate mofetil; GVHD: Graft-versus-host disease.